Biocomposites, an international medical devices company that engineers, manufactures and markets products for use in infection management in bone and soft tissue, has announced that research results comparing the efficacy of its calcium matrix products Stimulan and genex for antimicrobial potency and killing efficacy of bacterial biofilms, is being presented by Paul Stoodley at the American Academy of Orthopaedic Surgeons Annual Meeting (AAOS).
Paul Stoodley, PhD. director, Campus Microscopy and Imaging Facility (CMIF), professor, Departments of Microbial Infection and Immunity and Orthopaedics, Infectious Diseases Institute, The Ohio State University said: “I am excited to present this research, which shows the effectiveness of both calcium matrix products. Stimulan and genex present similar levels and durations of in vitro antimicrobial activity against pathogens common to orthopaedic infection, and significantly reduce bioburden in both planktonic and biofilm phenotypes. The global increase in infections caused by antibiotic resistant bacteria has required more targeted antibiotic treatment and the flexibility for surgeons managing infection to use their chosen antibiotics at patient-specific concentration levels.”
Michael Harris, chief executive officer of Biocomposites, added: “Against the backdrop of the pandemic, Biocomposites has continued to execute on its strategy of developing and delivering high quality, cost effective, essential products to healthcare systems and patients worldwide. We are delighted to present our research findings at this prestigious event, and to continue to demonstrate that our products can significantly improve patient outcomes.”
Since the last AAOS Annual Meeting, Biocomposites received European approval for mixing Stimulan with antibiotics: vancomycin, gentamicin and tobramycin, for use in infected bone and soft tissue, and Canadian approval for use in treating bacterial infection in soft tissue surrounding bone, making it the first and only approved calcium matrix that can carry an antibiotic to treat bacterial infection. Biocomposites also launched Stimulan Rapid Cure 3cc product in the US, designed specifically for smaller voids in foot and ankle, orthopaedic reconstruction and trauma procedures.
